Donna Neuberg is involved in collaborative research in cancer in several different settings. Dr. Neuberg is the director of the Biostatistics Core for the CLL Research Consortium. She is the coordinating statistician for the Eastern Cooperative Oncology Group (ECOG), where she works with multi-center clinical trials in breast cancer. She also works with researchers in autologous and allogeneic bone marrow transplantation for hematologic malignancies at the Dana-Farber Cancer Institute and the CRC, where issues of detection of minimal residual disease after curative therapy and the late complications of therapy are of particular interest.
Dr. Neuberg's methodological interests reflect her collaborative interests. She is currently involved in an examination of intermediate endpoints in controlled clinical trials and in particular, the reliability of time to progression or relapse as an indicator of improved survival. She is also exploring the recruitment of elderly patients to cancer clinical trials, using the ECOG database. Dr. Neuberg is also interested the efficient design of early phase clinical trials with multiple endpoints, and in the problems surrounding the analysis of data with missing observations over time.
Dana-Farber Cancer Institute
44 Binney Street
Mailstop: CLSB 11007
Boston, MA 02115